All News

2020

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More
Media Release / May 29, 2020

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Woman at a work bench
Featured News / May 27, 2020

Novartis at ASCO

Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO)

Read More
Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
Media Release / May 14, 2020

Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

Read More
Media Release / May 06, 2020

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Read More

April

Media Release / Apr 28, 2020

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

Read More
Media Release / Apr 22, 2020

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease

Read More
Media Release / Apr 22, 2020

Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

Read More

March

Maryam Hussain, Robotic Cognitive Automation Transformation and EU Lead at Novartis
Featured News / Mar 06, 2020

International Women’s Day 2020

To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More